Company Monitoring Page for Gilead-Sciences

latest headlines for company on cafepharma

Study: Gilead antiviral drug shows promise as a treatment for Ebola Sudan
Stat
Thu, 03/14/24 - 06:25 pm
Tags:
Gilead Sciences, obeldesivir, Ebola Sudan, antivirals
Gilead tries new triple-target T-cell engagers in $1.5B-plus Merus collab
Fierce Biotech
Wed, 03/6/24 - 11:30 am
Tags:
Gilead Sciences, Merus, T-cell engager
Gilead Secures $210M from VC to Build Trodelvy’s Clinical Case in NSCLC
BioSpace
Fri, 03/1/24 - 11:48 am
Tags:
Gilead Sciences, funding, Trodelvy, non-small cell lung cancer
6 first-half 2024 oncology data readouts to watch
BioSpace
Mon, 02/26/24 - 11:20 am
Tags:
oncology, clinical trials, Daiichi Sankyo, AstraZeneca, Enhertu, metastatic breast cancer, Gilead Sciences, Trodelvy, bladder cancer, GSK, Zejula, Jemperli, ovarian cancer, Roche, tiragolumab, Tecentriq, non-small cell lung cancer, Cue Biopharma, CUE-101, head and neck cancer, Elicio Therapeutics, ELI-002, solid tumors
PhRMA, navigating turbulence, taps Gilead CEO to helm board of directors
Fierce Pharma
Wed, 02/21/24 - 10:43 pm
Tags:
PhRMA, lobbying, Daniel O'Day, Gilead Sciences
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials
Reuters
Thu, 02/15/24 - 07:14 pm
Tags:
Gilead Sciences, magrolimab, solid tumors
Gilead pays $4.3B for CymaBay, the biotech that never gave up on liver disease med
Fierce Biotech
Mon, 02/12/24 - 11:53 am
Tags:
Gilead Sciences, CymaBay Therapeutics, M&A, liver disease, seladelpar, primary biliary cholangitis
FDA puts hold on Gilead's blood cancer therapy trials
Reuters
Wed, 02/7/24 - 09:20 pm
Tags:
Gilead Sciences, FDA, clinical trials, magrolimab, blood cancer
Gilead will not buy Tizona after paying $300M for the right to do so
Fierce Biotech
Wed, 02/7/24 - 11:17 am
Tags:
Gilead Sciences, Tizona Therapeutics, M&A, oncology
Amgen earnings boosted by Horizon deal, Gilead quarterly revenue drops
Medical Marketing and Media
Tue, 02/6/24 - 11:41 pm
Tags:
Amgen, Gilead Sciences, earnings, Horizon Therapeutics, M&A
Gilead-backed Kyverna Therapeutics aims for $857.3 mln valuation in upsized IPO
Reuters
Tue, 02/6/24 - 09:17 am
Tags:
Kyvera Therapeutics, IPOs, Gilead Sciences, autoimmune diseases
Gilead invests $320M in Arcus to increase stake to 33%
Medical Marketing and Media
Wed, 01/31/24 - 10:32 pm
Tags:
Gilead Sciences, Arcus Biosciences, immuno-oncology
Gilead’s Kite Gets FDA Approval for Faster CAR T Therapy Manufacturing
BioSpace
Wed, 01/31/24 - 11:58 am
Tags:
Gilead Sciences, Kite Pharma, FDA, drug manufacturing, Yescarta, CAR-T
Gilead stops phase 3 TIGIT trial, doubling down on other studies and pumping $320M into partner Arcus
Fierce Biotech
Tue, 01/30/24 - 10:34 am
Tags:
Gilead Sciences, Arcus Biosciences, Tigit, lung cancer, clinical trials
Gilead's Tecartus gets revised safety demand amid FDA's push for CAR-T boxed warnings
Fierce Pharma
Wed, 01/24/24 - 10:46 am
Tags:
Gilead Sciences, Tecartus, CAR-T, FDA
FDA requires 'boxed warning' for CAR-T cancer therapies
Reuters
Mon, 01/22/24 - 10:10 pm
Tags:
CAR-T, FDA, warnings, Gilead Sciences, JNJ, Novartis
Gilead's Trodelvy fails to extend survival in lung cancer study, prompting selloff
Fierce Pharma
Mon, 01/22/24 - 11:21 am
Tags:
Gilead Sciences, antibody-drug conjugate, Trodelvy, lung cancer, clinical trials
Gilead calls off Oceanside manufacturing expansion, uproots biologics development team
Fierce Pharma
Wed, 01/17/24 - 08:45 pm
Tags:
Gilead Sciences, biologics, California, drug manufacturing
CAR-T hype faces infrastructure reality check
Fierce Pharma
Tue, 01/16/24 - 09:22 am
Tags:
CAR-T, cell therapy, gene therapy, Gilead Sciences, JNJ
Gilead Sciences Must Face Consumer Claims Over Older, Lower-Quality Drugs, Court Rules
BioSpace
Fri, 01/12/24 - 11:34 am
Tags:
Gilead Sciences, legal, HUV

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.